Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

Transplantation

Volumn 66, Issue 12, 1998, Pages 1770-1779

  Davis, Connie L ^a,b   Wood, Brent L ^a   Sabath, Daniel E ^a   Joseph, Jackline S ^a   Stehman Breen, Catherine ^a   Broudy, Virginia C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Divsions Nephrology and Transplant ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LUNG NODULE; LUNG RESECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RECURRENCE;

EID: 0032573751     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00035     Document Type: Article

References (94)

1. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25(6): 367.
2. Nalesnik M, Jaffe R, Starzl T, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-Prednisone Immunosuppression. Am J Pathol 1988; 133(1): 173.
3. Hanto D, Gajl-Peczalska J, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983; 198(3): 356.
4. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 1996; 9(6): 621.
5. Swinnen L, Mullen G, Carr T, Costanzo M, Fischer R. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86(9): 3333.
6. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97(1): 14.
7. Cohen J. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991; 70(2): 137.
8. Shapiro R, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous γ-globulin. N Engl J Med 1988; 318: 1334.
9. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71(5): 1234.
10. Morgan G, Superina R. Lymphoproliferative disease after pediatric liver transplantation. J Pediatr Surg 1994; 29(9): 1192.
11. Cockfield S, Preiksaitis J, Jewell L, Parfrey N. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993; 56(1): 88.
12. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23(1): 1106.
13. Garnier JL, Berger F, Betuel H, et al. Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 1989; 4: 818.
14. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712.
15. Hickey D, Nalesnik M, Vivas C, et al. Renal retransplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease. Clin Transplant 1990; 4: 187.
16. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23(1): 1473.
17. Fischer Am, Blanche SM, Le Bidois JM, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451.
18. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996; 62(3): 370.
19. Weissmann DJM, Ferry JAM, Harris NLM, Louis DNM, Delmonico FM, Spiro IM. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748.
20. Lones M, Mishalani S, Shintaku I, Weiss L, Nichols S, Said J. Changes in tonsils and adenoids in children with posttransplant lymphoproliferative disorder: report of three cases with early involvement of Waldeyer's rings. Hum Pathol 1995; 26(5): 525.
21. Antoine C, Garnier JL, Duboust A, Bariety J, Stevenson G, Glotz D. Successful treatment of posttransplant lymphoproliferative disorder with renal graft preservation by monoclonal antibody therapy. Transplant Proc 1996; 28(5): 2825.
22. Mustafa MM, Winick NJ, Margraf LR. Epstein-Barr virus lymphoproliferative disorder in children with leukemia: case report and review of the literature. J Pediatr Hematol Oncol 1997; 19(1): 77.
23. McMillan E, Wasik R, Everett M. Identification of T-lymphocytes and T-subsets in human tonsil using monoclonal antibodies and the immunoperoxidase technic. Am J Clin Pathol 1981; 76(6): 737.
24. Gown A, Vogel A. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol 1984; 114(2): 309.
25. Gown A, de Wever N, Battifora H. Microwave-based antigenic unmasking: a revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1993; 1: 256.
26. Loughran T, Kidd P, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164.
27. Oda D, Persson G, Haigh W, Sabath D, Penn I, Aziz S. Oral presentation of posttransplantation lymphoproliferative disorders. Transplantation 1996; 61: 435.
28. Chang K, Chen Y-Y, Shibata D, Weiss L. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992; 1: 246.
29. Wilson W, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11(8): 1573.
30. Press O, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9(3): 423.
31. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 178.
32. Hanson M, Morrison V, Peterson B, et al. Posttransplant T-cell lymphoproliferative disorders, an aggressive, late complication of solid organ transplantation. Blood 1996; 88(9): 3626.
33. Starzl T, Porter K, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet 1984; 1: 583.
34. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20(5): 1346-.
35. Pirsch J, Stratta R, Sollinger H, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86(2): 241.
36. Gibel L, Harford A, Yogel LR, Spiegel J, Sterling W, Tung K. Renal transplant obstruction by B cell lymphoproliferative disorder: case report and review of the literature. J Urology 1988; 140: 593.
37. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, O'Reilly R. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591.
38. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84(3): 972.
39. Gutierrez MI, Judde J-G, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 1996; 56: 969.
40. Nalesnik M, Rao A, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63(9): 1200.
41. Purtilo DT. Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients. AIDS Res 1986; 2(Suppl 1): S177.
42. Okano M, Thiele GM, Kobayashi RH, et al. Interferon-γ in a family with x-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection. J Clin Immunol 1989; 9(1): 48.
43. Swinnen L, Costanzo-Nordin M, Fisher S, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323(25): 1723.
44. Thomas JA, Hotchin NA, Allday MJ, et al. Immunohistology of Epstein-Barr virus-associated antigens in b cell disorders from immunocompromised individuals. Transplantation 1990; 49(5): 944.
45. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14(6): 1943.
46. Rinde-Hoffman D, Cintron G, Ferguson J, Toole J, Bugni W. Lymphoproliferative disorder early after cardiac transplantation. Am J Cardiol 1991; 68: 1724.
47. Hagenbeek A, Carde P, Meerwaldt J, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 1998; 16(1): 41.
48. Krown S, Real F, Cunninghmam-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983; 308(18): 1071.
49. Woll P, Pettengell R. Interferons in oncology. Br J Clin Pract 1997; 51(2): 111.
50. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe d'etude des lymphomes folliculaires. J Clin Oncol 1997; 15(3): 1110.
51. Smalley R, Andersen J, Hawkins M, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336-1341.
52. Solal-Celigny P, Lepage E, Brousees N, et al. Recominant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 319: 1608.
53. Foon K, Maluish A, Abrams P, et al. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Am J Med 1986; 80: 351.
54. Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman J. Hematologic remission and cytogenetic improvement induced by recombinant human interferon a in chronic myelogenous leukemia. N Engl J Med 1986; 314 (17): 1065.
55. Balkwill F. Interferons. Lancet 1989; 1: 1060.
56. Quesada J, Reuben J, Manning J, Hersh E, Gutterman J. α interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310(1): 15.
57. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-α treatment in renal transplant recipients. Transplantation 1988; 45(2): 402.
58. Kramer P, ten Kate F, Bijnen A, Jeekel J, Weimar W. The pathology of interferon-induced renal allograft lesions. Transplant Proc 1985; 27(1): 58.
59. Magnone M, Holley J, Shapiro R, et al. Interferon α induced acute renal allograft rejection. Transplantation 1995; 59(7): 1068.
60. Thervet E, Pol S, Legendre C, Gagnadoux M-F, Cavalcanti R, Kreis H. Low dose recombinant leukocyte interferon-α treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 1994; 58(5): 625.
61. Cheeseman S, Rubin R, Stewart J, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N Engl J Med 1979; 300(24): 1345.
62. Hirsch M, Schooley R, Cosimi A, et al. Effects of interferon-α on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308(25): 1489.
63. Rostaing L, Izopet J, Baron E, Duffaut M, Fuel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon α in kidney transplant recipients. Transplantation 1995; 59(10): 1426.
64. Rostaing L, Modesto A, Baron E, Cisterne J, Chabannier M, Durand D. Acute renal failure in kidney transplant patients treated with interferon α 2b for chronic hepatitis C. Nephron 1996; 74: 512.
65. Averbach S, Austin H, Sherwin S, Antonovynch T, Bunn P, Longo D. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte interferon therapy for mycosis fungoides. N Engl J Med 1984; 310 (1): 32.
66. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. BMJ 1985; 290: 1180.
67. Sherwin S, Knost J, Fein S, et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982; 248(19): 2461.
68. Nassar G, Pedro P, Remmers R, Mohanty L, Smith W. Reversible renal failure in a patient with the hypereosinophilia syndrome during therapy with α interferon. Am J Kidney Dis 1998; 31(1): 121.
69. Herrman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with α-II interferon. N Engl J Med 1987; 112.
70. Weiss K. Nephrotic range of proteinuria and interferon therapy. Ann Intern Med 1992; 116(4): 347.
71. Kimmel P, Abraham A, Phillips T. Membranoproliferative glomerulonephritis in a patient treated with interferon-α for human immunodeficiency virus infection. Am J Kidney Dis 1994; 24(5): 858.
72. Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with α-interferon therapy for cutaneous T-cell lymphoma. Nephron 1994; 67: 94.
73. Horowitz R, Glicklich D, Sablay L, Wiernik P, Wadler S. Interferon-induced acute renal failure: a case report and literature review. Med Oncol 1995; 12: 55.
74. Rettmar K, Keinast J, Van de Loo J. Minimal change glomerulonephritis with reversible proteinuria during interferon α 2a therapy for chronic myeloid leukemia. Am J Hematol 1995; 49(4): 355.
75. Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T. Acute renal failure and nephrotic syndrome with α interferon therapy. Nephrol Dial Transplant 1997; 12(1): 200.
76. Ronnblom L, Aim G, Oberg K. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115(3): 178.
77. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon α. Am J Kidney Dis 1992; 20(5): 516.
78. Fleischmann M, Celerier P, Bernard P, Litous P, Dreno B. Long-term interferon-α therapy induces autoantibodies against epidermis. Dermatology 1996; 192; 50.
79. Blanche S, Le Deist F, Veber F, et al. Treatment of severe Epstein-Barr virus induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Ann Intern Med 1988; 108(2): 199.
80. Garnier J-L, Touraine J-L. Syndromes lymphoproliferatifs associes au virus d'Epstein-Barr en transplantation. Presse Med 1992; 21: 1994.
81. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13(4): 961.
82. Garnier J-L, Berger F, Martin X, et al. Post-transplant B-cell lymphomas-correlation of late stage B-cell differentiation and progression of disease; treatment with chimeric monoclonal antibody. Transplant Proc 1995; 27(2): 1777.
83. Chen Y, Shiao R, Labayog J, Modi S, Lavelle D. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma. Leuk Lymphoma 1997; 27(1-2): 11.
84. Preti H, Cabanillas F, Talpaz M, Tucker S, Seymour J, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127(3): 186.
85. Seymour J, Talpaz M, Hagemeister F, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 1997; 102(1): 21.
86. Tsunenari T, Akamatsu K, Kaiho S, et al. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Anticancer Res 1996; 16(5A): 2537.
87. Reittie J, Yong K, Panayiotidis P, Hoffbrand A. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22(1-2): 83.
88. Bataille R, Barlogie B, Lu Z, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86(2): 685.
89. Bataille R, Zhang X, Wijdenes J, Schved J, Klein B. Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. Med Oncol Tumor Pharmacother 1993; 10(4): 185.
90. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9.
91. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98.
92. Leblond F, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16(6): 2052.
93. Leibowitz D. Epstein-Barr virus and cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1431.
94. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338(24): 1741.